Post-Platinum Treatment Strategies in Advanced Urothelial Carcinoma

This segment examines how treatment for advanced urothelial (bladder) cancer has progressed beyond traditional platinum-based chemotherapy. The discussion begins with the long-standing reliance on cisplatin and carboplatin, noting that most patients can tolerate only four to six cycles because of cumulative toxicities such as fatigue, renal impairment, and neuropathy. Instead of stopping therapy and passively waiting for relapse, the speakers now routinely consider maintenance immunotherapy for patients whose disease has not progressed after platinum treatment.

They review key clinical trial data, including an early randomized phase II trial with pembrolizumab and a larger phase III trial with avelumab, both supporting a maintenance approach and demonstrating survival benefits. The segment highlights both the practical advantages (reducing the anxiety of treatment-free intervals) and the biologic rationale (using a non–cross-resistant therapy with a different safety profile), positioning maintenance immune checkpoint blockade as a core component of contemporary bladder cancer management.